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Study objectives: To test safety and tolerability of long-term moxifloxacin in
resistant tuberculosis (TB) patients and patients with intolerance to first line anti-TB
drugs.
Design: Clinical evaluation of adverse events (AEs) during prolonged moxifloxacin
treatment.
Setting: TB Unit of the Regional TB Reference Center, Villa Marelli Institute,
Niguarda Ca’Granda Hospital, Milan, Italy
Patients and interventions: Patients treated with moxifloxacin, 400mg orally once
daily for TB in the Villa Marelli Institute from January 2001 to December 2003 were
enrolled.
Results: Thirty-eight patients were treated with moxifloxacin at the Villa Marelli
Institute in the study period, for multidrug resistant (MDR) TB (14, 36.8%), for
intolerance to first line anti-TB drugs (9, 23.7%), for combined resistance and
intolerance to first line anti-TB drugs (12, 31.6%), other reasons (3, 7.9%). The mean
duration of moxifloxacin treatment was 6.375.2 months. Twelve (31.6%) patientsElsevier Ltd. All rights reserved.
tidrug-resistant; WHO, World Health Organization; MTB, Mycobacterium Tuberculosis Complex;
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Long-term moxifloxacin in complicated TB 1567reported at least an AE due to moxifloxacin, mostly gastrointestinal (8, 21.0%),
general (5, 13.2%) and central nervous system (3, 7.9%) AEs. In 4 (10.5%) patients the
drug was withdrawn for major AEs; no irreversible or fatal events were recorded.
Most of the patients (31, 81.6%) reported a treatment success, even if the success
rate was lower in MDR TB patients (8/14, 51.7%).
Conclusions: Despite the fact that a large proportion of patients experienced at
least an AE due to moxifloxacin, the drug resulted safe in the long-term
administration for complicated TB cases.
& 2006 Elsevier Ltd. All rights reserved.Introduction
The increasing prevalence of resistance to first line
anti-tuberculosis (TB) drugs in countries with a high
incidence of TB is a challenge to control pro-
grammes based on the World Health Organisation-
recommended strategy (DOTS strategy).1 High rates
of failure and relapses are recorded when standard
(or poorly modified) regimens are used for resistant
and multidrug-resistant (MDR) TB cases.2,3 The
development and implementation of the DOTS plus
strategy is crucial in the fight against TB at a global
level, and new regimens, including second line and
new anti-TB drugs, are urgently needed.4
New drugs highly active against Mycobacterium
tuberculosis (MTB) could improve treatment of
cases with resistance to first line drugs (especially
to isoniazid and rifampicin) and may shorten the
duration of current standard regimens. An ideal
drug should be highly active against MTB, it should
allow a once a day administration and it should be
well tolerated and safe, even in long-term regi-
mens. Quinolones are the first new class of drugs
introduced on the market with a proven in vitro
activity against MTB since rifampicin and interest is
increasing about their potential use both in the
treatment of complicated cases of TB and of latent
TB infection.4 Despite limited evidence is avail-
able, the current lack of choices makes the newer
quinolones the first alternative to rifampicin5 and
an asset for regimens tailored to treat MDR TB.6
New generation quinolones had been repeatedly
reported to have lower minimal bactericidal con-
centrations (MBCs), to be better tolerated, espe-
cially in prolonged administration7,8 and to improve
treatment outcomes9 of MDR TB cases. Sparfloxacin
was reported to be safe and effective in a
prospective series of patients with complicated
TB,10 even though its use is limited by AEs such as
photosensitazion.11 Retrospective series of patients
showed that levofloxacin is well tolerated,12 and
may be more effective than ofloxacin.13
Moxifloxacin has the highest in vitro activity
against MTB14 and its effect in vivo was demon-strated in a recent study aimed to assess the effect
on bacterial growth in patients with active
pulmonary TB.15
Very limited data are available on the safety and
tolerability of moxifloxacin in patients treated
either for drug resistant TB or because of intoler-
ance to first line drugs.16
We report the results of an observational study
on the use of moxifloxacin 400mg orally once daily,
given in combination with other anti-TB drugs for
the treatment of complicated TB patients, in order
to assess its safety and tolerability in long-term
treatment. Treatment outcomes are also reported.Materials and methods
Setting
The Villa Marelli Institute is an out-patient care TB
Unit with a catchment area of about 4 million
people. Patients diagnosed in the Institute or in
other hospitals of Lombardia Region are referred to
the TB Unit for treatment and follow up. The Unit is
a national reference centre for the treatment of
MDR TB cases. Its microbiology laboratory is the
National Reference Laboratory for Drug Suscept-
ibility Testing (DST) for mycobacteria, being part of
a national network of laboratories fulfilling the
principles of the Global Project on Anti-TB Drug
Resistance Surveillance (GPDRS). The DSTs for all
the patients described in this study were performed
for first line anti-TB drugs (except pirazinamide)
and ofloxacin, according to the proportion method.
The quality of DSTs is ensured by a once-a-year
supranational proficiency testing, performed ac-
cording to international standards.17Study design and protocol
All the 1231 TB patients, undergoing a complete set
of clinical, microbiological and laboratory exam-
inations at diagnosis and during follow-up (e.g.
medical assessment, chest radiographies and blood
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count and some other methabolic parameters such
as uric acid and glycemia-monthly or every 2
months according to the phase of treatment, the
case severity and evolution) treated at the study
site between January 1, 2001 and December 31,
2003 were enrolled. All their data were prospec-
tively recorded in an electronic database.
In particular, at each control visit all patients
were interviewed twice by a public health nurse
and subsequently by a chest physician about their
adherence to treatment and onset of AEs, all data
being recorded on their file.
Patients receiving 400mg orally once daily of
moxifloxacin (Avalox&, Bayer Pharmaceuticals, Mi-
lan, Italy) were retrospectively considered for
analysis of AEs due to this antibiotic. Reasons for
prescribing moxifloxacin were classified as resis-
tance to first line drugs, intolerance to first line
drugs or other reasons. The study was approved by
the local ethics committee.
Anti-TB regimens included at least 3 active
drugs, selected on the basis of DST results.18 For
MDR TB patients a treatment of at least 18 months
was programmed according to internal protocols.
Definitions recommended by WHO guidelines18
are implemented in the Unit and anti-TB regimens
are prescribed following major international guide-
lines.5,18 An immigrant was defined as a person born
in a country outside the European Union and the
other industrialized countries.19
MDR TB was defined as TB caused by strains of
MTB with a proven resistance to at least rifampicin
and isoniazid.20
Intolerance (as an inclusion criteria) was defined as
the occurrence of major AEs not allowing the
administration of a determinate drug to the patient.
AEs were classified as minor (not implying the
withdrawal of the drug) and major (causing the
discontinuation of the drug) according to WHO
guidelines.18 Criteria for attributing the AE to
moxifloxacin were their onset with the administra-
tion of the drug, the resolution (or improvement in
case of not reversible or partially reversible AEs)
with the withdrawal of the drug, the type of AE
(including only AEs most likely due to moxifloxacin
or quinolones, as reported in the literature8). In
detail, when AEs occurred, the drugs most likely
related to the phenomenon were temporarily
discontinued and then separately reintroduced in
order to assess their relation to symptoms.
Data analysis
Sensitive variables from patients treated with
moxifloxacin were analysed, including demographicdata (gender, age, ethnicity, immigration status),
TB case definition and category, pattern of resis-
tance as reported in the DST at the time of the first
administration of the drug, presence of intoler-
ance/major AEs to first line drugs, initial and
modified regimens adopted, duration of the use of
moxifloxacin, results of blood tests performed
before and during the treatment, concomitant
anti-TB drugs. Outcomes of patients were re-
corded, and stratified for MDR TB patients and
patients treated with moxifloxacin because of
intolerance to first line drugs.
Expected and observed frequencies were com-
pared by w2 test. A p value p0.05 was considered
statistically significant.Results
Thirty-eight patients (3.1% of all the cohort) were
prescribed anti-TB regimen containing moxifloxacin
for the treatment of active TB. The main reasons to
prescribe the drug were multidrug-resistance to
first line drugs alone (14 out of 38 patients, 36.8%),
intolerance to standard anti-TB treatment (9
patients, 23.7%), combined resistance (excluding
MDR) and intolerance to first line drugs (12
patients, 31.6%), other reasons (3 patients, 7.9%).
In details, in these latter 3 patients anti-TB
regimen included moxifloxacin respectively be-
cause of a previous anti-TB therapy completion
and relapse in a HIV seropositive patient; a relapse
in a patient with a psoas muscle abscess; progres-
sion of disease during therapy (1 patient).
Main demographic features of the patients, main
features of the disease and risk factors for TB are
reported in Table 1. Among the 26 patients with a
resistant strains, 7 (18.4%) were resistant to
isoniazid, 1 (2.6%) to rifampicin, 2 (5.3%) to
isoniazid and pirazinamide, 1 (2.6%) to isoniazid
and streptomycin and 14 (63.1%) were MDR TB
strains.
The mean duration of any anti-TB treatment in
the study group was 9.275.6 months. In the MDR
subgroup treatment lasted 17.3+6.8 months.
The mean duration of moxifloxacin treatment
was 6.375.2 months (median 5.7 months, ranging
from few days to 20.8 months). Table 2 shows the
anti-TB drugs used in combination with moxiflox-
acin. Thirty-two (84.2%) patients reported one or
more AEs during the administration of the com-
bined anti-TB treatment (Table 3). Overall, most of
the patients well tolerated moxifloxacin for the
duration of the treatment (26 out of 38, 68.4%).
Twelve (31.6%) patients reported at least an AE
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Table 1 Demographic features, WHO categories,
main risk factors for TB in the patients before being
treated with Moxifloxacin at the Villa Marelli
Institute, Milan, Italy 2001–2003.
Features N (%)
Main demographic features
Age (mean7SD) 43.6717.3
M/F 17/21 (44.7)
Immigrants 22 (57.9)
Weight (mean7SD) 58.5710.9
TB localization
Pulmonary TB 25 (65.8)
Extra-pulmonary TB 6 (15.8)
Pulm. and extra-pulm. TB 7 (18.4)
TB category
First diagnosis 18 (47.4)
Relapse 14 (36.8)
Chronic 4 (10.5)
Other 2 (5.3)
Risk factors for TB
Diabetes 2 (5.3)
Contact 14 (36.8)
Intravenous drugs 2 (5.3)
Alcohol 4 (10.5)
Viral hepatitis 2 (5.3)
Cancer 1 (2.6)
HIV seropositive status 2 (5.3)
Reason for prescribing moxifloxacin
Resistance to first line drugs 14 (36.8)
Intolerance 9 (23.7)
Combined resistance and
intolerance
11 (29.0)
Other reasons 4 (10.5)
Total 38 (100.0)
Table 2 Anti-TB drugs used in combination with
moxifloxacin in the TB patients treated at the Villa
Marelli Institute, Milan, Italy 2001–2003.
Drug N (%)
Moxifloxacin 38 (100)
Amikacin 6 (15.8)
Para-aminosalicylic acid 4 (10.5)
Clarithromycin 2 (5.3)
Ethambutol 28 (73.6)
Ethionamide 14 (36.8)
Isoniazid 10 (26.3)
Prothionamide 3 (7.9)
Pyrazinamide 20 (52.6)
Rifabutin 3 (7.9)
Rifampicin 17 (44.7)
Streptomycin 1 (2.6)
Terizidone 10 (26.3)
Long-term moxifloxacin in complicated TB 1569related to the use of moxifloxacin, which occurred
randomly throughout the treatment course. Seven
patients (18.4%) needed a temporary discontinua-
tion of the drug, mainly for nausea and vomiting,
asthenia and anorexia. One of them reported
tremors. A woman reported genital pain during
the treatment with moxifloxacin, which disap-
peared with the discontinuation and not repre-
sented when the drug was re-introduced. All these
patients did not present further AEs with moxiflox-
acin re-challenge.
Four (10.5%) out of the 12 (4/12, 33.3%) patients
reporting AEs due to moxifloxacin needed the
discontinuation of the treatment for one or more
major AEs. Main AEs reported by these patients
were nausea (2 patients) and vomiting (1 patient),
muscle pain (1 patient), dizziness and insomnia (1
patient), tremors (1 patient). One patient pre-
sented vaginitis.Treatment success (the sum of WHO categories
cured and treatment completed) was obtained in
31 (81.6%) patients. In particular, the success rate
was significantly lower in MDR TB patients (8/14,
51.7%) than in patients treated with moxifloxacin
for other reasons (23/24, 95.8%, P ¼ 0:01). Three
(7.9%) patients were defined as chronics at the end
of the treatment, 2 (5.3%) were lost and 2 (5.3%)
MDR TB patients died (for reasons independent by
the moxifloxacin administration).Discussion
Retrospective data have shown that the use of
quinolones is associated to a better outcome in MDR
TB cases9 and that newer molecules of this class
may be better tolerated and more effective.13 Few
data are available on the safety and tolerability of
newer quinolones in long-term anti-TB regi-
mens.10,12 Moxifloxacin is a very promising drug,
because of the lowest minimal bactericidal con-
centration (MBC) in vitro against MTB,14 and recent
in vivo data.21 However, the combination with
other anti-TB drugs and high dose of moxifloxacin
may be needed to prevent the development of
resistance.22 To the date, no fatal reaction due to
moxifloxacin administration has been reported, but
very limited data are available on long-term use,
especially in combination with other anti-TB drugs.
To our knowledge only case reports are available
on moxifloxacin safety in complicated TB cases.
Many of them were MDR TB patients, and the
use of the drug was considered life-saving. Other
patients were given moxifloxacin because of poor
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Table 3 Main adverse events (AE) reported by patients treated with moxifloxacin at the Villa Marelli Institute,
Milan, Italy 2001–2003, classified for AEs due to the overall anti-TB treatment (mean duration of the therapy
9.275.6 months (median 8.3 months, range 1.6–23.4 months) and to moxifloxacin and 6.375.2 months (median
5.7 months, ranging from few days to 20.8 months), respectively).
Anti-TB treatment Moxifloxacin
N (%)
Total (38)100
Patients reporting AEs 32 (84.2) 12 (31.6)
Gastrointestinal disorders 20 (52.6) 8 (21.0)
Abdominal pain 5 (13.2) 1 (2.6)
Constipation 1 (2.6) —
Diarrhoea 5 (13.2) —
Dyspepsia 1 (2.6) 1 (2.6)
Haematemesis 1 (2.6) —
Nausea 7 (18.4) 3 (7.9)
Vomiting 4 (10.5) 3 (7.9)
Nervous system disorders 16 (42.1) 3 (7.9)
Dizziness 1 (2.6) 1 (2.6)
Epilepsy 2 (5.3) —
Paresthesia 2 (5.3) —
Headache 5 (13.2) —
Loss of consciousness 1 (2.6) —
Tremors 4 (10.5) 1 (2.6)
Depression 1 (2.6) —
Insomnia 2 (5.3) 1 (2.6)
General disorders 13 (34.2) 5 (13.2)
Asthenia 5 (13.2) 3 (7.9)
Oedema (site of administration) 1 (2.6) —
Pain 1 (2.6) 1 (2.6)
Fever 3 (7.9) —
Anorexia 3 (7.9) 1 (2.6)
Musculoskeletal system 6 (15.8) 2 (5.3)
Arthralgia 5 (13.2) 2 (5.3)
Myalgia 1 (2.6) —
Eyes 4 (10.5) 1 (2.6)
Eye irritation 1 (2.6) 1 (2.6)
Visual disturbance 3 (7.9) —
Infection-infestations 3 (7.9) 1 (2.6)
Abscess (site of administration) 1 (2.6) —
Esophageal candidiasis 1 (2.6) —
Vaginitis 1 (2.6) 1 (2.6)
Skin 3 (7.9) —
Erythema 1 ( 2.6) —
Rash macular 2 (5.3) —
Ear and labyrinth disorders 1 (2.6) —
Auditory deficit 1 (2.6) —
L.R. Codecasa et al.1570tolerability to first line drugs or for other particular
clinical conditions. Moxifloxacin was always used in
combination with other first and/or second line
drugs, and most of the patients reported side-effects to anti-TB treatment, highlighting the
difficult management of this cohort. Our patients
received moxifloxacin for a mean of 6 months. AEs
were correlated to moxifloxacin on the basis of the
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tion with administration, withdrawn, re-challenge.
Overall, this quinolone was well tolerated, even if
at least one out of four patients reported an AE.
Almost 20% (7 patients) reported gastrointestinal
disorders (mainly nausea and vomiting) due to
moxifloxacin. This proportion of AEs seems to be
higher compared to the frequency of nausea and
vomiting in patients affected by respiratory
tract infections treated with quinolones for 5–14
days,8 but it may be explained by the longer
duration of the treatment and the combination
with other drugs. Two of these patients required
the discontinuation of the drug, whilst in 5 patients
the AEs were transitory, resolved by the disconti-
nuation of moxifloxacin and without preventing
the re-introduction of the drug in the anti-TB
treatment.
Quinolones are known to penetrate the hema-
toencephalic barrier, and this can explain some AE
occurring in our cohort of patients, like dizziness,
tremors and insomnia, as well as asthenia and
anorexia. Three out of 4 of our patients who
needed a discontinuation of the drug complained
these AEs. Considering the chondrotoxicity of
quinolones,23 it is not surprising that 2 patients of
our cohort reported arthalgia. The case of vaginitis
can be explained by the prolonged effect of
moxifloxacin on the normal vaginal flora.24 One
patient reported eye irritation: corneal deposits of
quinolones were also described,25 and this should
be taken in consideration when prescribing long-
term quinolones.
A recent study26 discussed the important issue of
the new quinolones safety in patients at increased
risk of cardiac toxicity. None of our patients
reported serious cardiac AEs: EKG data were
available only for 8 patients and none repeated
the EKG during the study period. Moxifloxacin
showed safe in our limited experience. However,
the patients described in our study were mostly
young and had no risk for cardiac complications.
The analysis of outcomes revealed a lower
success rate for patients treated with moxifloxacin
modified regimens because of MDR TB, compared to
patients treated for intolerance to first line drugs
or resistance other than MDR TB, highlighting the
tolerability of the drug until the end of the
treatment in patients who already experienced
severe AE.
Although larger studies are necessary to define
more clearly the role of moxifloxacin in the
treatment of MDR and complicated TB cases, the
results of our study suggest that the long-term use
of the drug is safe, most of the AEs reported being
mild and reversible (discontinuation of the drugnecessary only in 4 patients, complaining mostly
gastrointestinal and Central Nervous System AEs).References
1. Espinal MA. The global situation of MDR-TB. Tuberculosis
(Edinburgh) 2003;83(1–3):44–51.
2. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG,
Migliori GB, et al. Standard short-course chemotherapy for
drug-resistant tuberculosis: treatment outcomes in 6 coun-
tries. J Am Med Assoc 2000;283(19):2537–45.
3. Migliori GB, Espinal M, Danilova ID, Punga VV, Grzemska M,
Raviglione MC. Frequency of recurrence among MDR-tB
cases ‘successfully’ treated with standardised short-
course chemotherapy. Int J Tuberc Lung Dis 2002;6(10):
858–64.
4. O’Brien RJ. Studies of the early bactericidal activity of
new drugs for tuberculosis: a help or a hindrance to
antituberculosis drug development? Am J Respir Crit Care
Med 2002;166(1):3–4.
5. Treatment of tuberculosis. MMWR Recomm Rep 2003;52
(RR-11):1–77.
6. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, Shin SS,
et al. Programmes and principles in treatment of multidrug-
resistant tuberculosis. Lancet 2004;363(9407):474–81.
7. Garcia-Tapia A, Rodriguez JC, Ruiz M, Royo G. Action of
fluoroquinolones and Linezolid on logarithmic- and station-
ary-phase culture of Mycobacterium tuberculosis. Che-
motherapy 2004;50(5):211–3.
8. Ball P, Stahlmann R, Kubin R, Choudhri S, Owens R. Safety
profile of oral and intravenous moxifloxacin: cumulative
data from clinical trials and postmarketing studies. Clin Ther
2004;26(7):940–50.
9. Tahaoglu K, Torun T, Sevim T, Atac G, Kir A, Karasulu L, et al.
The treatment of multidrug-resistant tuberculosis in Turkey.
N Engl J Med 2001;345(3):170–4.
10. Lubasch A, Erbes R, Mauch H, Lode H. Sparfloxacin in the
treatment of drug resistant tuberculosis or intolerance of
first line therapy. Eur Respir J 2001;17(4):641–6.
11. Dawe RS, Ibbotson SH, Sanderson JB, Thomson EM, Ferguson
J. A randomized controlled trial (volunteer study) of
sitafloxacin, enoxacin, levofloxacin and sparfloxacin photo-
toxicity. Br J Dermatol 2003;149(6):1232–41.
12. Richeldi L, Covi M, Ferrara G, Franco F, Vailati P, Meschiari E,
et al. Clinical use of Levofloxacin in the long-term treatment
of drug resistant tuberculosis. Monaldi Arch Chest Dis
2002;57(1):39–43.
13. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC,
et al. Comparative roles of levofloxacin and ofloxacin in the
treatment of multidrug-resistant tuberculosis: preliminary
results of a retrospective study from Hong Kong. Chest
2003;124(4):1476–81.
14. Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of
moxifloxacin, levofloxacin, gatifloxacin and linezolid against
Mycobacterium tuberculosis. Int J Antimicrob Agents 2002;
20(6):464–7.
15. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG,
Nyindo M, et al. The bactericidal activity of moxifloxacin in
patients with pulmonary tuberculosis. Am J Respir Crit Care
Med 2003;168(11):1342–5.
16. Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G,
Bellanova S. Long-term tolerance and effectiveness of
moxifloxacin therapy for tuberculosis: preliminary results.
J Chemother 2003;15(1):66–70.
ARTICLE IN PRESS
L.R. Codecasa et al.157217. Migliori GB, Centis R, Fattorini L, Besozzi G, Saltini C, Orefici
G, et al. Monitoring the quality of laboratories and the
prevalence of resistance to antituberculosis drugs: Italy,
1998–2000. Eur Respir J 2003;21(1):129–34.
18. Maher D, Chaulet P, Spinaci S, Harries A. Treatment of
tuberculosis: guidelines for national programmes, 3rd ed.
Geneva, Switzerland, 2003.
19. Veen J, Perrocheau A, Schwoebel V. Surveillance of
tuberculosis in the WHO European region in 1995: results
of the feasibility study. Euro Surveill 1998;3(1):2–5.
20. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L,
Horsburgh Jr CR. Treatment of 171 patients with pulmonary
tuberculosis resistant to isoniazid and rifampin. N Engl J Med
1993;328(8):527–32.
21. Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode
H. Early bactericidal activity of moxifloxacin in treatment of
pulmonary tuberculosis: a prospective, randomized study.
Antimicrob Agents Chemother 2004;48(3):780–2.
22. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M,
Drusano GL. Selection of a moxifloxacin dose that suppressesdrug resistance in Mycobacterium tuberculosis, by use of an
in vitro pharmacodynamic infection model and mathema-
tical modeling. J Infect Dis 2004;190(9):1642–51.
23. Burkhardt O, Kohnlein T, Pap T, Welte T. Recurrent tendinitis
after treatment with two different fluoroquinolones. Scand
J Infect Dis 2004;36(4):315–6.
24. Weis M, Hendrick K, Tillotson G, Gravelle K. Multicenter
comparative trial of ciprofloxacin versus cefuroxime axetil
in the treatment of acute rhinosinusitis in a primary care
setting. Rhinosinusitis Investigation Group. Clin Ther 1998;
20(5):921–32.
25. Castillo A, Benitez del Castillo JM, Toledano N, Diaz-Valle D,
Sayagues O, Garcia-Sanchez J. Deposits of topical norflox-
acin in the treatment of bacterial keratitis. Cornea 1997;
16(4):420–3.
26. Morganroth J, Dimarco JP, Anzueto A, Niederman MS,
Choudhri S. A randomized trial comparing the cardiac
rhythm safety of moxifloxacin vs levofloxacin in elderly
patients hospitalized with community-acquired pneumonia.
Chest 2005;128:3398–406.
